+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Companion Diagnostics Market by Technology Type, by Indication - Global Opportunity Analysis and Industry Forecast, 2020 - 2030

  • ID: 5314549
  • Report
  • January 2021
  • Region: Global
  • 300 pages
  • Next Move Strategy Consulting

FEATURED COMPANIES

  • ARUP Laboratories, Inc.
  • BioMerieux SA
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • MORE
Market Definition:

The Global Companion Diagnostics Market size was valued at USD 1.96 billion in 2019 and is predicted to reach USD 9.02 billion by 2030, with a CAGR of 14.8% from 2020-2030. Companion Diagnostic (CDx) is a clinical test co-developed with a therapeutic drug for screening the responders and non-responders to that particular drug. It is done in order to identify a patient group that can or cannot be treated with that corresponding drug. CDx helps practitioners to determine the benefits, side effects, and risks associated with the intake of therapeutic drugs, thereby ensuring patient’s safety.

Market Dynamics and Trends:

The increasing preferences for targeted therapies, growing applications of personalized medicines, higher prevalence of chronic diseases, and increasing incidences of allergies in patients due to side effects of medicines; give rise to development of customized CDx, thereby propagating the growth of global Companion Diagnostics market Additionally, the benefits offered by CDx test such as cost-effectiveness, high sensitivity, fast and accurate results in less time frames; further escalates the growth of Companion Diagnostics market.

According to data provided by World Health Organization in 2018; 1 in 6 deaths are caused due to cancer every year. At global level, an estimated 6.8 million people die every year suffering from neurological disorders. CDx holds wide application for indication, in chronic disorders such as oncology, neurology, and others. This scenario further supplements the growth of global Companion Diagnostics market. However, costly R&D procedures to develop new CDx, and unfavorable reimbursement policies, restricts the growth of global Companion Diagnostics market. On the other hand, upsurge in R&D activities, and increasing number of approvals granted by the U.S Food Drug Administration (FDA), are expected to propagate the growth of global Companion Diagnostics market in coming future.

Market Segmentations and Scope of the Study:

The global companion diagnostics market share has been analyzed based on technology, type, indication, and geography. Based on technology, the market is segmented into Immunohistochemistry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), In Situ Hybridization, and others. Based on indication, the market is divided into Oncology, Neurology, and others. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America is expected to dominate the global companion diagnostics market, throughout the forecast period, accounting for the highest market share. This is attributed to well-established healthcare infrastructures and medical laboratories, increased investments in R&D activities to develop advanced companion diagnostics, as well as growing preferences towards personalized medicinal therapies in this region.

Asia Pacific region is expected to grow substantially in the global companion diagnostics market, with the highest CAGR values, owing to improving healthcare facilities, increased geriatric population prone to cancer & neurological disorders, as well as increasing medical tourism in this region.

Competitive Landscape:

The companion diagnostics market is highly competitive and consists of various market players. Some of the major market players include Abbott Laboratories Molecular, Inc., ARUP Laboratories, Inc., Agilent (Dako Denmark A/S), Danaher Corporation (Leica Microsystems), BioMerieux SA, Foundation Medicine, Inc., Qiagen N.V., Myriad Genetics, Inc., Thermo Fisher Scientific (Life Technologies Corporation), and Roche (Ventana Medical Systems, Inc.) among others.

The key players are employing strategies such as joint ventures for co-developing new products, and acquisitions, in-order to gain stronger position in the companion diagnostics market. For instance, in March 2020, Thermo Fisher Scientific, one of the major players of companion diagnostics market, announced the signing of an agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson, to co-develop a CDx for cancer. Thermo Fisher's Oncomine Dx Target Test contains 46 cancer-related biomarkers for detection of both DNA and RNA variants. Its workflow features fast turnaround time and lowest sample requirements as compared to conventional oncology tests.

In June 2020, Thermo Fisher Scientific, announced that it has extended its strategic partnership with Agios Pharmaceuticals, by signing an extended agreement to co-develop a global CDx for Low-Grade Glioma (LGG) in oncology. This CDx test includes the identification of IDH gene mutations using the Ion Torrent Genexus System and Oncomine Precision Assay test, for LGG patients.

KEY MARKET SEGMENTS:
  • Global Companion Diagnostics market - By Technology Type
  • Immunohistochemistry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • In Situ Hybridization
  • Others
  • Global Companion Diagnostics market - By Indication
  • Oncology
  • Neurology
  • Others
  • Global Companion Diagnostics market -By Geography
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Australia
  • Rest of Asia-Pacific
  • RoW
  • South Africa
  • Brazil
  • Remaining countries
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ARUP Laboratories, Inc.
  • BioMerieux SA
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • MORE
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1 Secondary Research
1.2.2 Data Analysis Framework
1.2.3 Market Size Estimation
1.2.4 Forecasting
1.2.5 Primary Research and Data Validation

2. Market Snapshot, 2019-2030 Million USD
2.1. Market Snapshot

3. Porter's Five Force Model Analysis

4. Market Dynamics
4.1. Growth Drivers
4.1.1 Driver 1
4.1.2 Driver 2
4.1.3 Driver 3
4.1.4 Driver 4
4.2. Challenges
4.2.1 Challenge 1
4.2.2 Challenge 2
4.3. Opportunities
4.3.1 Opportunity 1
4.3.2 Opportunity 2

5. Global Companion Diagnostics Market, by Technology
5.1. Overview
5.2. Immunohistochemistry
5.2.1 Immunohistochemistry Market, by Region
5.2.1.1 North America Immunohistochemistry Market, by Country
5.2.1.2 Europe Immunohistochemistry Market, by Country
5.2.1.3 Asia-Pacific Immunohistochemistry Market, by Country
5.2.1.4 Rest of World Immunohistochemistry Market, by Country
5.3. Polymerase Chain Reaction (Pcr)
5.3.1 Polymerase Chain Reaction (Pcr) Market, by Region
5.3.1.1 North America Polymerase Chain Reaction (Pcr) Market, by Country
5.3.1.2 Europe Polymerase Chain Reaction (Pcr) Market, by Country
5.3.1.3 Asia-Pacific Polymerase Chain Reaction (Pcr) Market, by Country
5.3.1.4 Rest of World Polymerase Chain Reaction (Pcr) Market, by Country
5.4. Next Generation Sequencing (Ngs)
5.4.1 Next Generation Sequencing (Ngs) Market, by Region
5.4.1.1 North America Next Generation Sequencing (Ngs) Market, by Country
5.4.1.2 Europe Next Generation Sequencing (Ngs) Market, by Country
5.4.1.3 Asia-Pacific Next Generation Sequencing (Ngs) Market, by Country
5.4.1.4 Rest of World Next Generation Sequencing (Ngs) Market, by Country
5.5. in Situ Hybridization
5.5.1 in Situ Hybridization Market, by Region
5.5.1.1 North America in Situ Hybridization Market, by Country
5.5.1.2 Europe in Situ Hybridization Market, by Country
5.5.1.3 Asia-Pacific in Situ Hybridization Market, by Country
5.5.1.4 Rest of World in Situ Hybridization Market, by Country
5.6. Other Technology
5.6.1 Other Technology Market, by Region
5.6.1.1 North America Other Technology Market, by Country
5.6.1.2 Europe Other Technology Market, by Country
5.6.1.3 Asia-Pacific Other Technology Market, by Country
5.6.1.4 Rest of World Other Technology Market, by Country

6. Global Companion Diagnostics Market, by Indication
6.1. Overview
6.2. Oncology
6.2.1 Global Oncology Market, by Indication
6.2.1.1 Lung Cancer Market, by Region
6.2.1.1.1 North America Lung Cancer Market, by Country
6.2.1.1.2 Europe Lung Cancer Market, by Country
6.2.1.1.3 Asia-Pacific Lung Cancer Market, by Country
6.2.1.1.4 Rest of World Lung Cancer Market, by Country
6.2.1.2 Colorectal Cancer Market, by Region
6.2.1.2.1 North America Colorectal Cancer Market, by Country
6.2.1.2.2 Europe Colorectal Cancer Market, by Country
6.2.1.2.3 Asia-Pacific Colorectal Cancer Market, by Country
6.2.1.2.4 Rest of World Colorectal Cancer Market, by Country
6.2.1.3 Breast Cancer Market, by Region
6.2.1.3.1 North America Breast Cancer Market, by Country
6.2.1.3.2 Europe Breast Cancer Market, by Country
6.2.1.3.3 Asia-Pacific Breast Cancer Market, by Country
6.2.1.3.4 Rest of World Breast Cancer Market, by Country
6.2.1.4 Blood Cancer Market, by Region
6.2.1.4.1 North America Blood Cancer Market, by Country
6.2.1.4.2 Europe Blood Cancer Market, by Country
6.2.1.4.3 Asia-Pacific Blood Cancer Market, by Country
6.2.1.4.4 Rest of World Blood Cancer Market, by Country
6.2.1.5 Others Market, by Region
6.2.1.5.1 North America Others Market, by Country
6.2.1.5.2 Europe Others Market, by Country
6.2.1.5.3 Asia-Pacific Others Market, by Country
6.2.1.5.4 Rest of World Others Market, by Country
6.2.2 Oncology Market, by Region
6.2.2.1 North America Oncology Market, by Country
6.2.2.2 Europe Oncology Market, by Country
6.2.2.3 Asia-Pacific Oncology Market, by Country
6.2.2.4 Rest of World Oncology Market, by Country
6.3. Neurology
6.3.1 Neurology Market, by Region
6.3.1.1 North America Neurology Market, by Country
6.3.1.2 Europe Neurology Market, by Country
6.3.1.3 Asia-Pacific Neurology Market, by Country
6.3.1.4 Rest of World Neurology Market, by Country
6.4. Other Indication
6.4.1 Other Indication Market, by Region
6.4.1.1 North America Other Indication Market, by Country
6.4.1.2 Europe Other Indication Market, by Country
6.4.1.3 Asia-Pacific Other Indication Market, by Country
6.4.1.4 Rest of World Other Indication Market, by Country

7. Global Companion Diagnostics Market, by Region
7.1. Overview
7.2. North America
7.2.1 North America Companion Diagnostics Market, by Technology
7.2.2 North America Companion Diagnostics Market, by Indication
7.2.2.1 North America Oncology Market, by Indication
7.2.3 North America Companion Diagnostics, Market by Country
7.2.3.1 U.S.
7.2.3.1.1 U.S. Companion Diagnostics Market, by Technology
7.2.3.1.2 U.S. Companion Diagnostics Market, by Indication
7.2.3.1.2.1. U.S. Oncology Market, by Indication
7.2.3.2 Canada
7.2.3.2.1 Canada Companion Diagnostics Market, by Technology
7.2.3.2.2 Canada Companion Diagnostics Market, by Indication
7.2.3.2.2.1. Canada Oncology Market, by Indication
7.2.3.3 Mexico
7.2.3.3.1 Mexico Companion Diagnostics Market, by Technology
7.2.3.3.2 Mexico Companion Diagnostics Market, by Indication
7.2.3.3.2.1. Mexico Oncology Market, by Indication
7.3. Europe
7.3.1 Europe Companion Diagnostics Market, by Technology
7.3.2 Europe Companion Diagnostics Market, by Indication
7.3.2.1 Europe Oncology Market, by Indication
7.3.3 Europe Companion Diagnostics, Market by Country
7.3.3.1 Germany
7.3.3.1.1 Germany Companion Diagnostics Market, by Technology
7.3.3.1.2 Germany Companion Diagnostics Market, by Indication
7.3.3.1.2.1. Germany Oncology Market, by Indication
7.3.3.2 UK
7.3.3.2.1 UK Companion Diagnostics Market, by Technology
7.3.3.2.2 UK Companion Diagnostics Market, by Indication
7.3.3.2.2.1. UK Oncology Market, by Indication
7.3.3.3 France
7.3.3.3.1 France Companion Diagnostics Market, by Technology
7.3.3.3.2 France Companion Diagnostics Market, by Indication
7.3.3.3.2.1. France Oncology Market, by Indication
7.3.3.4 Rest of Europe
7.3.3.4.1 Rest of Europe Companion Diagnostics Market, by Technology
7.3.3.4.2 Rest of Europe Companion Diagnostics Market, by Indication
7.3.3.4.2.1. Rest of Europe Oncology Market, by Indication
7.4. Asia-Pacific
7.4.1 Asia-Pacific Companion Diagnostics Market, by Technology
7.4.2 Asia-Pacific Companion Diagnostics Market, by Indication
7.4.2.1 Asia-Pacific Oncology Market, by Indication
7.4.3 Asia-Pacific Companion Diagnostics, Market by Country
7.4.3.1 Australia
7.4.3.1.1 Australia Companion Diagnostics Market, by Technology
7.4.3.1.2 Australia Companion Diagnostics Market, by Indication
7.4.3.1.2.1. Australia Oncology Market, by Indication
7.4.3.2 Japan
7.4.3.2.1 Japan Companion Diagnostics Market, by Technology
7.4.3.2.2 Japan Companion Diagnostics Market, by Indication
7.4.3.2.2.1. Japan Oncology Market, by Indication
7.4.3.3 China
7.4.3.3.1 China Companion Diagnostics Market, by Technology
7.4.3.3.2 China Companion Diagnostics Market, by Indication
7.4.3.3.2.1. China Oncology Market, by Indication
7.4.3.4 Rest of Asia-Pacific
7.4.3.4.1 Rest of Asia-Pacific Companion Diagnostics Market, by Technology
7.4.3.4.2 Rest of Asia-Pacific Companion Diagnostics Market, by Indication
7.4.3.4.2.1. Rest of Asia-Pacific Oncology Market, by Indication
7.5. Rest of World
7.5.1 Rest of World Companion Diagnostics Market, by Technology
7.5.2 Rest of World Companion Diagnostics Market, by Indication
7.5.2.1 Rest of World Oncology Market, by Indication
7.5.3 Rest of World Companion Diagnostics, Market by Country
7.5.3.1 Brazil
7.5.3.1.1 Brazil Companion Diagnostics Market, by Technology
7.5.3.1.2 Brazil Companion Diagnostics Market, by Indication
7.5.3.1.2.1. Brazil Oncology Market, by Indication
7.5.3.2 South Africa
7.5.3.2.1 South Africa Companion Diagnostics Market, by Technology
7.5.3.2.2 South Africa Companion Diagnostics Market, by Indication
7.5.3.2.2.1. South Africa Oncology Market, by Indication
7.5.3.3 Remaining Countries
7.5.3.3.1 Remaining Countries Companion Diagnostics Market, by Technology
7.5.3.3.2 Remaining Countries Companion Diagnostics Market, by Indication
7.5.3.3.2.1. Remaining Countries Oncology Market, by Indication

8. Company Profiles
8.1. Abbott Laboratories Molecular, Inc.
8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Operating Business Segments
8.1.4 Product Portfolio
8.1.5 Business Performance
8.1.6 Key Strategic Moves and Development
8.2. Agilent
8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Operating Business Segments
8.2.4 Product Portfolio
8.2.5 Business Performance
8.2.6 Key Strategic Moves and Development
8.3. Arup Laboratories, Inc.
8.3.1 Company Overview
8.3.2 Company Snapshot
8.3.3 Operating Business Segments
8.3.4 Product Portfolio
8.3.5 Business Performance
8.3.6 Key Strategic Moves and Development
8.4. Biomerieux
8.4.1 Company Overview
8.4.2 Company Snapshot
8.4.3 Operating Business Segments
8.4.4 Product Portfolio
8.4.5 Business Performance
8.4.6 Key Strategic Moves and Development
8.5. Danaher Corporation
8.5.1 Company Overview
8.5.2 Company Snapshot
8.5.3 Operating Business Segments
8.5.4 Product Portfolio
8.5.5 Business Performance
8.5.6 Key Strategic Moves and Development
8.6. Foundation Medicine, Inc.
8.6.1 Company Overview
8.6.2 Company Snapshot
8.6.3 Operating Business Segments
8.6.4 Product Portfolio
8.6.5 Business Performance
8.6.6 Key Strategic Moves and Development
8.7. Myriad Genetics, Inc.
8.7.1 Company Overview
8.7.2 Company Snapshot
8.7.3 Operating Business Segments
8.7.4 Product Portfolio
8.7.5 Business Performance
8.7.6 Key Strategic Moves and Development
8.8. Roche
8.8.1 Company Overview
8.8.2 Company Snapshot
8.8.3 Operating Business Segments
8.8.4 Product Portfolio
8.8.5 Business Performance
8.8.6 Key Strategic Moves and Development
8.9. Thermo Fisher Scientific
8.9.1 Company Overview
8.9.2 Company Snapshot
8.9.3 Operating Business Segments
8.9.4 Product Portfolio
8.9.5 Business Performance
8.9.6 Key Strategic Moves and Development
8.10. Qiagen N.V.
8.10.1 Company Overview
8.10.2 Company Snapshot
8.10.3 Operating Business Segments
8.10.4 Product Portfolio
8.10.5 Business Performance
8.10.6 Key Strategic Moves and Development
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ARUP Laboratories, Inc.
  • BioMerieux SA
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • MORE
Companion Diagnostic: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2020 - 2030. Upsurge in R&D activities, and increasing number of approvals granted by the U.S Food Drug Administration (FDA), are factors expected to drive the growth of global companion diagnostics market.

Companion Diagnostic (CDx) is a clinical test co-developed with a therapeutic drug for screening the responders and non-responders to that particular drug. It is done in order to identify a patient group that can or cannot be treated with that corresponding drug. CDx helps practitioners to determine the benefits, side effects, and risks associated with the intake of therapeutic drugs, thereby ensuring patient’s safety.

The increasing preferences for targeted therapies, growing applications of personalized medicines, higher prevalence of chronic diseases, and increasing incidences of allergies in patients due to side effects of medicines; give rise to development of customized CDx, thereby propagating the growth of global Companion Diagnostics market.

The global companion diagnostics market share has been analyzed based on technology, type, indication, and geography. Based on technology, the market is segmented into Immunohistochemistry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), In Situ Hybridization, and others. Based on indication, the market is divided into Oncology, Neurology, and others. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
Note: Product cover images may vary from those shown
  • Abbott Laboratories Molecular, Inc.
  • ARUP Laboratories, Inc.
  • Agilent (Dako Denmark A/S)
  • Danaher Corporation (Leica Microsystems)
  • BioMerieux SA
  • Foundation Medicine, Inc.
  • Qiagen N.V.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific (Life Technologies Corporation)
  • Roche (Ventana Medical Systems, Inc.)
Note: Product cover images may vary from those shown
Adroll
adroll